Alicyclic Ring Containing Patents (Class 514/690)
  • Publication number: 20120201830
    Abstract: Provided are compositions and methods for the treatment of macular edema, in particular that results from central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), age related macular degeneration (AMD), diabetes, or eye surgical procedures. The composition strengthens retinal health through the prevention, stabilization and/or treatment of macular edema. The composition can include polyphenolic compounds extracted from natural plants, an alpha lipoic acid, docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA), and ubiquinone.
    Type: Application
    Filed: February 2, 2012
    Publication date: August 9, 2012
    Inventors: Zhuning MA, Jingran Chen
  • Patent number: 8236860
    Abstract: The present invention relates to a novel application of a compound. The compound 4--2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of pancreatic cancer cells and be used as a pharmaceutical composition to inhibit the pancreatic tumor growth.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: August 7, 2012
    Assignee: Golden Biotechnology Corporation
    Inventors: Sheng-Yun Liu, Wu-Che Wen, Mao-Tien Kuo
  • Publication number: 20120195873
    Abstract: Nutritional compositions and methods of using the nutritional compositions with exercise to attenuate the loss of functional status are provided. In a general embodiment, the present disclosure provides a nutritional composition including whey protein, and Vitamin D. The nutritional composition and exercise can be specifically used to attenuate the loss of functional status, especially in the elderly.
    Type: Application
    Filed: July 15, 2010
    Publication date: August 2, 2012
    Applicant: NESTEC S.A.
    Inventors: Kevin Burke Miller, Ingo Arne Jurk, Zamzam Kabiry Roughead
  • Publication number: 20120195871
    Abstract: An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.
    Type: Application
    Filed: April 11, 2012
    Publication date: August 2, 2012
    Inventors: Christopher J MILLEY, Scott E. Peters
  • Publication number: 20120195946
    Abstract: Topical compositions containing lysate of human parthenogenetic stem cells (hpSCs), preferably within a liposomal dispersion, that reduce the visible signs of skin aging and/or cellulite.
    Type: Application
    Filed: August 2, 2011
    Publication date: August 2, 2012
    Inventors: Andrey Semechkin, Nikolay A. Turovets, Larisa S. Agapova, Ruslan A. Semechkin, Jeffrey D. Janus
  • Patent number: 8227401
    Abstract: (Problem) The object of the invention relates to a development of a new musk-feeling fragrance material which is a highly scenting musk-feeling fragrance, and is to provide a fragrance composition which, when added to fragrances or cosmetics, can improve the fixative property and express a high performance and excellent musky aromatic quality. (Means for resolution) A fragrance composition is prepared using, as the active ingredient, a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 90:10 to 95:5 (weight ratio) in terms of weight ratio, or a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 75:25 to 80:20 (weight ratio) in terms of weight ratio.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: July 24, 2012
    Assignee: Takasago International Corporation
    Inventors: Kenichi Yamamoto, Misao Yagi, Hiroyuki Matsuda, Kenji Maruyama
  • Publication number: 20120183522
    Abstract: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders.
    Type: Application
    Filed: March 26, 2012
    Publication date: July 19, 2012
    Applicant: DECODE GENETICS EHF
    Inventors: Jasbir Singh, Mark E. Gurney, Alex Burgin, Vincent Sandanayaka, Alexander Kiselyov, Adalie Motta, Gary Schiltz, Georgeta Hategan, Timothy Hagen
  • Publication number: 20120183521
    Abstract: A nutriceutical supplement for use in equines provides enhanced mitochondrial energizing activity and reduced inflammation and results in enhanced resistance to training injuries and diseases and enhances peak racing performance. The supplement is provided along with equine feed as a formulation including at least Coenzyme Q10, Carnitine, d-Ribose, Boswellia extract and Curcumin. These ingredients provide enhanced mitochondrial energizing activity and reduced stress, inflammation and injuries.
    Type: Application
    Filed: January 18, 2012
    Publication date: July 19, 2012
    Inventors: Stephen T. Sinatra, Stanley N. Jankowitz
  • Publication number: 20120184513
    Abstract: The invention relates to organic compounds having the ability to reduce or suppress the onset of skin irritation induced by extraneous cause selected from the group of 2-heptylcyclopentanone, 2-ethoxynaphthalene; 2-methoxynaphthalene; 1-methoxy-4-(prop-1-enyl)benzene; 1-(cyclopropylmethyl)-4-methoxybenzene; wherein X, Y, and R1 to R11 have the same meaning as given in the description. Furthermore the invention refers to compositions for topical application to the skin comprising them. It further relates to a method of reducing or suppressing the formation of skin irritation.
    Type: Application
    Filed: January 14, 2011
    Publication date: July 19, 2012
    Applicant: Givaudan SA
    Inventors: Andreas NATSCH, Michael WASESCHA
  • Publication number: 20120184625
    Abstract: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more ?-diones, particularly ?-diketones and ?-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The present invention is further directed to processes of preparing ?-diones by de novo synthesis or from natural sources such as volatile oil-bearing plants from families including Alliaceae, Apiaceae, Asteraceae, Cannabinaceae, Lamiaceae, Pteridaceae, Myrtaceae, Myoporaceae, Proteaceae, Rutaceae and Zingiberaceae.
    Type: Application
    Filed: March 27, 2012
    Publication date: July 19, 2012
    Applicants: University of Western Sydney, Bioprospect Limited
    Inventors: Robert Neil Spooner-Hart, Albert Habib Basta
  • Patent number: 8221736
    Abstract: cis-Jasmone has been discovered to be useful as a semiochemical that changes the behavior of insects and/or the physiology of plants. It has direct signalling roles with plant-feeding aphids, in attraction of aphid predators and parasitoids, and may act as an airborne signal inducing production of volatile plant semiochemicals, including the monoterpene (E)-?-ocimene, that stimulate foraging by parasitoids. It is an extremely benign compound having, to human beings, a pleasant aroma and gives a long-lasting effect after removal of the stimulus.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: July 17, 2012
    Assignee: Rothamsted Research Limited
    Inventors: Alastair James Hick, John Anthony Pickett, Lester John Wadhams, Johnathan Andrew Napier
  • Publication number: 20120171186
    Abstract: A method for producing a nutraceutical composition comprising a combination of oil soluble antioxidants derived from an edible oil and water soluble antioxidants derived from a plant extract, wherein the plant extract further provides a natural surfactant; and the nutraceutical composition produced by that method.
    Type: Application
    Filed: April 19, 2010
    Publication date: July 5, 2012
    Inventor: Woon San Liang
  • Publication number: 20120172450
    Abstract: A formulation comprising jasmonate for improving skeletal muscle function in a mammal, particularly a human is provided. This may be accomplished by reducing muscle fatigue and/or increasing skeletal muscle performance.
    Type: Application
    Filed: December 9, 2011
    Publication date: July 5, 2012
    Applicant: BROADY HEALTH SCIENCES, LLC
    Inventor: Brunde Broady
  • Publication number: 20120164215
    Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.
    Type: Application
    Filed: March 1, 2012
    Publication date: June 28, 2012
    Inventors: Sung Lan HSIA, Niven Rajin Narain, Jie Li, Kathryn J. Russell, Karrune V. Woan, Indushekhar Persaud
  • Publication number: 20120156185
    Abstract: The present invention provide edible compositions comprising soluble and insoluble dietary fibers at a ratio of about 1:1 ratio, having a palatable taste, useful for reducing the serum lipid content in a mammal, and further for reducing the blood glucose level, enhancing the feeling of satiety and keeping a desired body weight.
    Type: Application
    Filed: August 31, 2010
    Publication date: June 21, 2012
    Applicant: HERBAMED LTD.
    Inventors: Anat Solomon, Haim Aviv
  • Publication number: 20120156286
    Abstract: Disclosed are compositions comprising Coenzyme Q10 and a cetylated fatty acid blend, pharmaceutical formulations comprising the same and methods of increasing the systemic concentration of Coenzyme Q10 in an individual, comprising administering the same to the individual.
    Type: Application
    Filed: July 27, 2011
    Publication date: June 21, 2012
    Applicant: IMAGENETIX, INC.
    Inventor: William P. SPENCER
  • Patent number: 8202911
    Abstract: In one aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of general formula (I), wherein R1-R6, Ra-Rc, Q, Y1, Y2 and n are as defined herein, whereby the composition is formulated for administration to a subject at a dosage between about 0.1 mg/kg to about 50 mg/kg of body weight. In another aspect, the present invention provides a method for treating breast tumor metastasis in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the inventive composition described directly above and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: June 19, 2012
    Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Xin-Yun Huang, Samuel J. Danishefsky, Christoph Gaul, Jón T. Njardarson
  • Publication number: 20120149655
    Abstract: A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and use of jasmonate for treating bladder dysfunction is provided.
    Type: Application
    Filed: December 9, 2011
    Publication date: June 14, 2012
    Applicant: BROADY HEALTH SCIENCES, LLC
    Inventor: Brunde Broady
  • Publication number: 20120141448
    Abstract: Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of phosphatidic acid for administration is phosphatidic acid-enriched lecithin. Creatine is co-administered orally to increase the muscle-building and strength effect. Other suggested additives include nutritional and herbal supplements, micronutrients and hormones.
    Type: Application
    Filed: November 23, 2011
    Publication date: June 7, 2012
    Inventors: Lorenzo De Ferra, Marvin Heuer, Scott Hagerman, Martin Purpura, Ralf Jäger
  • Publication number: 20120141447
    Abstract: A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to about 7 wt. % magnesium, from about 0.25 to about 6.0 wt. % zinc, from about 0.001 to about 0.02 wt. % selenium, from about 0.1 to about 10 wt. % manganese, from about 5 to about 50 wt. % ginger root P.E. 4:1., from about 5 to about 40 wt. % citrus bioflavonoids, from about 2.5 to about 40 wt. % 1-cystine, from about 5 to about 40 wt. % n-acetlyl-1-carnitine, from about 1 to about 40 wt. % alpha lipoic acid, from about 1 to about 40 wt. % coenzyme Q10, from about 1 to about 40 wt. % green tea extract, and from about 1 to about 60 wt. % resveratrol.
    Type: Application
    Filed: September 26, 2011
    Publication date: June 7, 2012
    Inventor: Ford D. Albritton, IV
  • Publication number: 20120141424
    Abstract: The present invention is directed to materials and methods for the treatment of hypertension and ischemia comprising administering at least one therapeutic agent selected from the group consisting of vascular endothelial growth factor-C product and vascular endothelial growth factor-D product, and optionally, when treating hypertension, a standard of care anti-hypertensive agent.
    Type: Application
    Filed: January 7, 2010
    Publication date: June 7, 2012
    Applicant: VEGENICS PTY LIMITED
    Inventors: Kari Alitalo, Tuomas Tammela, Georgia Zarkada, Denis Tvorogov
  • Publication number: 20120141391
    Abstract: The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system.
    Type: Application
    Filed: June 29, 2011
    Publication date: June 7, 2012
    Applicant: AVICENA GROUP, INC.
    Inventor: Rima Kaddurah-Daouk
  • Publication number: 20120134976
    Abstract: An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and c. sinensis, where each is present in an amount effective to counteract and/or prevent effects of aging in a subject when administered to the subject. The effects of aging can include age-related changes in gene expression.
    Type: Application
    Filed: May 24, 2011
    Publication date: May 31, 2012
    Inventors: Angela Mastaloudis, Steve Wood, Richard Weindruch, Tomas Alberto Prolla, Jamie Louis Barger, Mark Bartlett, Scott B. Ferguson, Joseph Chang
  • Publication number: 20120136068
    Abstract: The present invention relates to an agent for improving renal dysfunction comprising as an active ingredient a compound represented by the following formula (1): wherein each R1, R2, and R3 represents a hydrogen atom or a methyl group, and X represents a linear or branched alkylene or alkenylene group having 10 to 28 carbon atoms.
    Type: Application
    Filed: February 7, 2012
    Publication date: May 31, 2012
    Applicant: MEIJI CO., LTD.
    Inventors: Keisuke Sato, Motoaki Saito, Bang Luu, Masashi Yamada, Hiroto Suzuki
  • Publication number: 20120128769
    Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.
    Type: Application
    Filed: February 2, 2012
    Publication date: May 24, 2012
    Applicant: Soft Gel Technologies, Inc.
    Inventor: Michael Fantuzzi
  • Publication number: 20120128777
    Abstract: The invention is related to compositions which can be used as dermal formulations for supporting the skin to restore normal conditions in case of e.g. irritated skin, or to support medical therapy of skin with atopic dermatitis symptoms, atopic dermatitis, psoriasis or related diseases (e.g. accompanied by distorted barrier function of the skin and microbial load). The compositions of the invention can be used for dermo-cosmetic products but also for pharmaceutical/-medical products, depending on the composition and the additional actives incorporated (cosmetic actives or drugs). The invention is based on the synergistic effect of metallic particles, in particular silver particles (such as microsilver, nanosilver) and lipid particles (lipid nanoparticles or lipid microparticles). As alternatives to silver particles, other metallic particles (e.g. zinc, copper) or nanocrystalline actives can be incorporated (e.g.
    Type: Application
    Filed: October 26, 2009
    Publication date: May 24, 2012
    Applicant: PHARMASOL GMBH
    Inventors: Cornelia Keck, Kay Schwabe, Christian Rimpler
  • Publication number: 20120121566
    Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.
    Type: Application
    Filed: January 24, 2012
    Publication date: May 17, 2012
    Applicant: Soft Gel Technologies, Inc.
    Inventor: Michael Fantuzzi
  • Publication number: 20120122994
    Abstract: An object of the present invention is to provide a new insecticidal compound by paying attention to the insecticidal activity contained in the flower part of marigold, and to provide an insecticide containing the compound as an active ingredient. There are provided an insecticidal compound represented by the following chemical formula: [Formula 1], and an insecticide containing the insecticidal compound as an active ingredient or an insecticide containing, as active ingredients, the insecticidal compound and an insecticidal compound represented by the following chemical formula: [Formula 2], wherein the insecticide can exhibit extraordinary insecticidal efficacy compared with existing pyrethroid-based insecticidal compounds.
    Type: Application
    Filed: August 31, 2011
    Publication date: May 17, 2012
    Inventors: Yoshio KATSUDA, Masafumi INOUE, Masamichi OKAMOTO
  • Publication number: 20120121567
    Abstract: An ophthalmic solution containing riboflavin and at least a compound chosen in the group composed of essential and conditionally essential amino acids, coenzyme Q, L-proline, glycine, lysine hydrochloride, L-leucine, L-arginine and compounds intended to stimulate the production of metalloproteinase MMP9 for the protection of internal structures of the eyeball against UV-A rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique.
    Type: Application
    Filed: July 23, 2010
    Publication date: May 17, 2012
    Inventors: Salvatore Troisi, Antonio Del Prete, Ciro Caruso
  • Publication number: 20120114625
    Abstract: Shelf-stable fermented dairy products and methods of making the shelf-stable fermented dairy products are provided. The shelf-stable fermented dairy products can be shelf-stable with improved taste, viscosity and texture profiles. In a general embodiment, the present disclosure provides a shelf-stable fermented dairy product including a shelf-stable fermented dairy component, a stabilizer, and a puree composition. The shelf-stable fermented dairy component can be, for example, yogurt, sour cream, buttermilk or a combination thereof.
    Type: Application
    Filed: April 23, 2010
    Publication date: May 10, 2012
    Inventors: Ana Lucia Wiessel, Allen Bruce Zerlaut, Frank Karl Welch
  • Publication number: 20120114572
    Abstract: A method of reducing photodegradation of a coenzyme Q10 compound when exposed to UV radiation in a composition containing said coenzyme Q10 compound comprising combining with said coenzyme Q10 compound a compound of formula (I) in an amount effective to quench singlet excited state energy from the coenzyme Q10 compound and transfer the singlet excited state energy from the coenzyme Q10 compound to the compound of formula (I), wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, and the non-alkoxy R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, thereby photostabilizing the retinoid compound.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 10, 2012
    Applicant: HALLSTAR INNOVATIONS CORP.
    Inventors: Craig A. Bonda, Anna Pavlovic, Jean Zhang
  • Publication number: 20120108671
    Abstract: The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (?)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, activate GPR120, inhibit inflammation, and treat conditions responsive to PPAR? modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 3, 2012
    Inventors: Brian J. Carroll, Gary Darland, Anuradha Desai, Veera Konda, Clinton J. Dahlberg, Jan Urban
  • Publication number: 20120107374
    Abstract: The coenzyme Q10-containing liquid composition is obtained by dispersing and emulsifying coenzyme Q10 in an aqueous liquid containing a water-soluble substance consisting of octenylsuccinate starch and dextrin, and glycerin. The liquid composition may be dried to prepare a coenzyme Q10-containing solid composition.
    Type: Application
    Filed: January 11, 2012
    Publication date: May 3, 2012
    Inventors: HIROYUKI IKEMOTO, Tsuyoushi Minemura
  • Publication number: 20120107428
    Abstract: Provided herein are essential oils and synthetic compounds, and combinations thereof, as repellent compositions for repelling insects, such as vespid social wasps (Vespidae), including yellowjackets, paper wasps, and hornets. Controlled release devices comprising these repellent compositions are also provided.
    Type: Application
    Filed: August 9, 2011
    Publication date: May 3, 2012
    Applicant: Sterling International Inc.
    Inventors: Rodney G. Schneidmiller, Qing-He Zhang, Doreen R. Hoover
  • Publication number: 20120100120
    Abstract: An aqueous composition specifically adapted for supporting physical performance. The liquid composition comprises ribose, a saccharide such as glucose or dextrose, coenzyme Q10, ATP, caffeine, and D-pinitol in conjunction with minerals and electrolytes. The orally-consumed liquid composition may be sold in solid form, such as a powder, granulate, or tablet to be added to water or other fluid, or it may be sold as a shelf-stable ready-to-drink liquid. The liquid composition physiologically enhances essential energy stores and provides a supply of ingredients which support physiological generation and regeneration of ATP.
    Type: Application
    Filed: September 21, 2011
    Publication date: April 26, 2012
    Inventors: Ralph Mario Ferrante, Chad Kevin Cunningham
  • Publication number: 20120101169
    Abstract: The present invention is directed to methods of providing anticoagulation effects in subjects in need thereof, comprising administering to the subjects at least twice a day compounds of the present invention, stereoisomers, and racemates thereof.
    Type: Application
    Filed: July 11, 2011
    Publication date: April 26, 2012
    Applicant: Penwest Pharmaceuticals Co.
    Inventor: Amale HAWI
  • Publication number: 20120100122
    Abstract: A pharmaceutical composition containing a mitochondrial electron transport chain enhancer (or an antioxidant) and a compound of formula (I) shown in the specification. This pharmaceutical composition can be used to treat neurodegenerative disorders.
    Type: Application
    Filed: October 18, 2011
    Publication date: April 26, 2012
    Applicant: ChemiGen
    Inventor: Yansheng Du
  • Publication number: 20120087871
    Abstract: Methods for killing insects and a nest are disclosed. The methods may be used to disrupt a colony of nestdwelling insects. The insects may include wasps, hornets, and yellowjackets.
    Type: Application
    Filed: September 30, 2011
    Publication date: April 12, 2012
    Applicant: STERLING INTERNATIONAL INC.
    Inventors: Rodney G. Schneidmiller, Qing-He Zhang, Guiji Zhou, Doreen R. Hoover
  • Patent number: 8153146
    Abstract: The invention is an organic pesticide or fungicide made from components of hop extract by preparing stable aqueous emulsions of hop acids and other hop extract components. The hop acids and other hop extract components are suspended as stable, colloidal preparations in water, which can be sprayed on plants for pest control.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: April 10, 2012
    Assignee: John I. Haas
    Inventors: Gene Probasco, Mark M. Bossert, David W. Hysert
  • Publication number: 20120076766
    Abstract: A method of selecting the constituent elements of a therapeutic composition for application to wounds having a pathogen load is disclosed.
    Type: Application
    Filed: April 21, 2011
    Publication date: March 29, 2012
    Inventors: D. Howard Phillips, Steven Keough
  • Publication number: 20120076740
    Abstract: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents.
    Type: Application
    Filed: December 5, 2011
    Publication date: March 29, 2012
    Inventor: Eric H. Kuhrts
  • Patent number: 8143316
    Abstract: The present invention provides a method for treating peripheral vascular diseases in a mammalian subject, which comprises administering to the patient in need thereof an effective amount of 11-deoxy-prostaglandin compound.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: March 27, 2012
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Publication number: 20120064054
    Abstract: The present invention relates to pharmaceutical compositions active in preventing, stabilizing and treating Alzheimer's disease and cognitive dysfunctions related thereto.
    Type: Application
    Filed: March 5, 2010
    Publication date: March 15, 2012
    Inventor: Umberto Cornelli
  • Publication number: 20120058965
    Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.
    Type: Application
    Filed: June 17, 2011
    Publication date: March 8, 2012
    Inventors: William A. GODDARD, III, Mark MENNA, Stephen PANDOL, Ravinder ABROL
  • Publication number: 20120046359
    Abstract: Control or repellency of bed bugs by bringing the bed bugs into contact with a bed bug control formulation containing at least one compound selected from the group consisting of certain alkyl ketones and cyclic ketones wherein the total number of carbon atoms in the alkyl ketones and cyclic ketones is from 10 to 16 carbon atoms and method for achieving such control or repellency.
    Type: Application
    Filed: October 27, 2011
    Publication date: February 23, 2012
    Inventor: Robert H. Bedoukian
  • Publication number: 20120041072
    Abstract: A compound having inhibitory activity on the binding of a substance ? to a PTGS suppressor protein, wherein the substance ? has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein.
    Type: Application
    Filed: June 15, 2011
    Publication date: February 16, 2012
    Applicants: HOKKAIDO UNIVERSITY, NIPPON SODA CO., LTD.
    Inventors: Shinsuke Sano, Takako Fukagawa, Hirokazu Yamada, Chikara Masuta, Hanako Shimura
  • Publication number: 20120014934
    Abstract: A natural color is concentrated to intensify color range and to provide useful amounts of one or more of anti-oxidant, nutritional, and anti-inflammatory compounds derived from one or more pigment sources. In a preferred embodiment, the pigment source is a fruit, a vegetable, a legume, a spice, algae, or a combination thereof.
    Type: Application
    Filed: July 13, 2011
    Publication date: January 19, 2012
    Inventors: Paul Altaffer, Jeffrey M. Wuagneux, Pi-Yu Hsu
  • Publication number: 20120009169
    Abstract: A phospholipid gel is spontaneously formed when combining a first phospholipid, a second phospholipid, and water, wherein the first phospholipid is a neutral phospholipid and the second phospholipid is a negatively charged phospholipid. The first and second phospholipids are of natural origin, semi-synthetic origin, or synthetic origin. Preferably, they are di(C8-C22 acyl) phosphatidyl choline and di(C8-C22 acyl) phosphatidyl glycerol. The total phospholipid concentration is within a range of 6-40% by weight.
    Type: Application
    Filed: August 18, 2011
    Publication date: January 12, 2012
    Applicant: MCS MICRO CARRIER SYSTEMS GMBH
    Inventor: Julia Eva DIEDERICHS
  • Publication number: 20120010233
    Abstract: Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3?,5?-adenosine monophosphate. Specific compositions of the invention are also novel.
    Type: Application
    Filed: June 7, 2011
    Publication date: January 12, 2012
    Applicants: Board of Regents, The University of Texas, Mission Pharmacal Co.
    Inventors: Catherine H. Schein, Scott R. Gilbertson, Johnny W. Peterson, Deliang Chen, Maria Esterlla-Jimenez, Mary A. Walter, Jian Gao
  • Patent number: RE43280
    Abstract: The use of the reduction products of hyperforin and adhyperforin, pharmaceutically acceptable salts or esters thereof, in the pharmaceutical and/or nutritional field, in particular in the treatment of depression and Alzheimer's disease.
    Type: Grant
    Filed: April 18, 2003
    Date of Patent: March 27, 2012
    Assignee: Indena S.p.A.
    Inventors: Ezio Bombardelli, Paolo Morazzoni, Antonella Riva, Nicola Fuzzati